• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

酵母中 FMD 病毒样颗粒的表达及其与 CpG 和铝佐剂联合的免疫原性。

Expression of FMD virus-like particles in yeast and immunogenicity of combine with CpG and aluminum adjuvant.

机构信息

College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.

Grand Theravac Life Sciences (Nanjing) Co., Ltd., Nanjing 210000, China.

出版信息

J Vet Sci. 2023 Jan;24(1):e15. doi: 10.4142/jvs.22227.

DOI:10.4142/jvs.22227
PMID:36726280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9899949/
Abstract

BACKGROUND

Inactivated vaccines are limited in preventing foot-and-mouth disease (FMD) due to safety problems. Recombinant virus-like particles (VLPs) are an excellent candidate for a novel vaccine for preventing FMD, given that VLPs have similar immunogenicity as natural viruses and are replication- and infection-incompetent.

OBJECTIVES

The 3C protease and P1 polyprotein of type O FMD virus (FDMV) was expressed in yeast to generate self-resembling VLPs, and the potential of recombinant VLPs as an FMD vaccine was evaluated.

METHODS

BALB/c mice were immunized with recombinant purified VLPs using CpG oligodeoxynucleotide and aluminum hydroxide gel as an adjuvant. Cytokines and lymphocytes from serum and spleen were analyzed by enzyme-linked immunosorbent assay, enzyme-linked immunospot assay, and flow cytometry.

RESULTS

The VLPs of FMD were purified successfully from yeast protein with a diameter of approximately 25 nm. The immunization of mice showed that animals produced high levels of FMDV antibodies and a higher level of antibodies for a longer time. In addition, higher levels of interferon-γ and CD4 T cells were observed in mice immunized with VLPs.

CONCLUSIONS

The expression of VLPs of FMD in provides a novel strategy for the generation of the FMDV vaccine.

摘要

背景

由于安全性问题，灭活疫苗在预防口蹄疫（FMD）方面效果有限。鉴于病毒样颗粒（VLPs）具有与天然病毒相似的免疫原性，且不具有复制和感染能力，因此它们是预防 FMD 的新型疫苗的极佳候选物。

目的

本研究旨在通过酵母表达系统表达口蹄疫病毒（FMDV）的 3C 蛋白酶和 P1 多蛋白，以生成具有自我相似性的 VLPs，并评估重组 VLPs 作为 FMD 疫苗的潜力。

方法

使用 CpG 寡脱氧核苷酸和氢氧化铝凝胶作为佐剂，用重组纯化的 VLPs 对 BALB/c 小鼠进行免疫。通过酶联免疫吸附试验、酶联免疫斑点试验和流式细胞术分析血清和脾脏中的细胞因子和淋巴细胞。

结果

成功从酵母蛋白中纯化出直径约为 25nm 的 FMD VLP。小鼠免疫结果表明，动物产生了高水平的 FMDV 抗体，且抗体水平维持时间更长。此外，在接受 VLPs 免疫的小鼠中观察到更高水平的干扰素-γ和 CD4 T 细胞。

结论

在酵母中表达 FMD VLPs 为 FMDV 疫苗的生成提供了一种新策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/46a3218fafc0/jvs-24-e15-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/b06f87a67922/jvs-24-e15-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/c0f209934cb4/jvs-24-e15-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/b38f3e757e10/jvs-24-e15-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/63ca7a68816a/jvs-24-e15-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/35c06ab6182e/jvs-24-e15-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/6b6ea3c48a1d/jvs-24-e15-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/5b992bed9af9/jvs-24-e15-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/46a3218fafc0/jvs-24-e15-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/b06f87a67922/jvs-24-e15-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/c0f209934cb4/jvs-24-e15-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/b38f3e757e10/jvs-24-e15-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/63ca7a68816a/jvs-24-e15-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/35c06ab6182e/jvs-24-e15-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/6b6ea3c48a1d/jvs-24-e15-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/5b992bed9af9/jvs-24-e15-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8519/9899949/46a3218fafc0/jvs-24-e15-g008.jpg

相似文献

1
Expression of FMD virus-like particles in yeast and immunogenicity of combine with CpG and aluminum adjuvant.酵母中 FMD 病毒样颗粒的表达及其与 CpG 和铝佐剂联合的免疫原性。
J Vet Sci. 2023 Jan;24(1):e15. doi: 10.4142/jvs.22227.
2
Novel expression of immunogenic foot-and-mouth disease virus-like particles in Nicotiana benthamiana.在本氏烟中新型表达具有免疫原性的口蹄疫病毒样颗粒。
Virus Res. 2018 Jan 15;244:213-217. doi: 10.1016/j.virusres.2017.11.027. Epub 2017 Dec 1.
3
FMD empty capsids combined with the Immunostant Particle Adjuvant -ISPA or ISA206 induce protective immunity against foot and mouth disease virus.口蹄疫空衣壳与免疫增强颗粒佐剂（ISPA）或ISA206联合使用可诱导针对口蹄疫病毒的保护性免疫。
Virus Res. 2021 May;297:198339. doi: 10.1016/j.virusres.2021.198339. Epub 2021 Feb 14.
4
Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs.口蹄疫病毒O型病毒样颗粒（VLP）疫苗与聚肌胞苷酸（poly I:C）或CpG佐剂联合使用在豚鼠中的比较效力
Biologicals. 2015 Nov;43(6):437-43. doi: 10.1016/j.biologicals.2015.09.004. Epub 2015 Oct 20.
5
Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge.新型免疫原性杆状病毒表达的口蹄疫病毒样颗粒可保护豚鼠免受攻毒。
Res Vet Sci. 2013 Dec;95(3):1217-23. doi: 10.1016/j.rvsc.2013.07.007. Epub 2013 Aug 19.
6
Golden-star nanoparticles as adjuvant effectively promotes immune response to foot-and-mouth disease virus-like particles vaccine.金纳米星作为佐剂可有效增强口蹄疫病毒样颗粒疫苗的免疫应答。
Vaccine. 2018 Oct 29;36(45):6752-6760. doi: 10.1016/j.vaccine.2018.09.030. Epub 2018 Sep 26.
7
Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot-and-mouth disease virus as a bivalent vaccine candidate.人工设计的乙型肝炎病毒核心颗粒，由口蹄疫病毒 A 型和 O 型的多个表位组成，作为一种双价疫苗候选物。
J Med Virol. 2019 Dec;91(12):2142-2152. doi: 10.1002/jmv.25554. Epub 2019 Aug 24.
8
Nanoparticulate chitosan-TNF-α-VLPs activate mast cells and enhance adaptive immunity induced by foot-and-mouth disease virus-like particles in mice.纳米粒壳聚糖-TNF-α-VLPs 激活肥大细胞并增强小鼠口蹄疫病毒样颗粒诱导的适应性免疫。
Vet Immunol Immunopathol. 2023 Oct;264:110662. doi: 10.1016/j.vetimm.2023.110662. Epub 2023 Oct 15.
9
BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs.BacMam 表达的高度糖基化猪干扰素 α 可在猪中诱导针对口蹄疫病毒的强大抗病毒和佐剂作用。
J Virol. 2022 Jun 22;96(12):e0052822. doi: 10.1128/jvi.00528-22. Epub 2022 May 23.
10
Immunogenicity of adenovirus-derived porcine parvovirus-like particles displaying B and T cell epitopes of foot-and-mouth disease.展示口蹄疫B细胞和T细胞表位的腺病毒衍生猪细小病毒样颗粒的免疫原性
Vaccine. 2016 Jan 20;34(4):578-585. doi: 10.1016/j.vaccine.2015.11.003. Epub 2015 Dec 9.

引用本文的文献

1
Foot-and-mouth disease: genomic and proteomic structure, antigenic sites, serotype relationships, immune evasion, recent vaccine development strategies, and future perspectives.口蹄疫：基因组和蛋白质组结构、抗原位点、血清型关系、免疫逃逸、近期疫苗开发策略及未来展望
Vet Res. 2025 Apr 7;56(1):78. doi: 10.1186/s13567-025-01485-0.
2
Neutralizing Antibody Screening Using NanoBiT-Based Virus-like Particles of Foot-and-Mouth Disease Type Asia1 Enhances Biosafety and Sensitivity.利用基于纳米BiT的亚洲1型口蹄疫病毒样颗粒进行中和抗体筛选可提高生物安全性和灵敏度。
Viruses. 2025 Feb 27;17(3):337. doi: 10.3390/v17030337.
3
Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design.

本文引用的文献

1
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.鼻腔接种疫苗诱导针对 SARS-CoV-2 变体的交叉保护分泌型 IgA 抗体，降低肺嗜酸性免疫病理学的潜在风险。
Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26.
2
The High Immunity Induced by the Virus-Like Particles of Foot-and-Mouth Disease Virus Serotype O.O型口蹄疫病毒样颗粒诱导的高免疫力
Front Vet Sci. 2021 Feb 25;8:633706. doi: 10.3389/fvets.2021.633706. eCollection 2021.
3
New horizons in adjuvants for vaccine development.
口蹄疫病毒的毒力与免疫逃逸策略：对疫苗设计的启示
Vaccines (Basel). 2024 Sep 19;12(9):1071. doi: 10.3390/vaccines12091071.
疫苗开发佐剂的新领域。
Curr Opin Immunol. 2020 Aug;65:97-101. doi: 10.1016/j.coi.2020.08.008. Epub 2020 Oct 8.
4
CpG Oligonucleotides as Vaccine Adjuvants.CpG 寡核苷酸作为疫苗佐剂。
Methods Mol Biol. 2021;2197:51-85. doi: 10.1007/978-1-0716-0872-2_4.
5
Foot-and-Mouth Disease Virus: Immunobiology, Advances in Vaccines and Vaccination Strategies Addressing Vaccine Failures-An Indian Perspective.口蹄疫病毒：免疫生物学、疫苗进展以及应对疫苗失效的疫苗接种策略——印度视角
Vaccines (Basel). 2019 Aug 16;7(3):90. doi: 10.3390/vaccines7030090.
6
Advances in Using as Chassis for Recombinant Protein Production.利用[具体内容]作为重组蛋白生产底盘的研究进展。 （你提供的原文“Using ”后面似乎缺失了具体信息）
Front Bioeng Biotechnol. 2019 May 1;7:94. doi: 10.3389/fbioe.2019.00094. eCollection 2019.
7
Immunogenicity and protective efficacy of a novel foot-and-mouth disease virus empty-capsid-like particle with improved acid stability.一种具有改善酸稳定性的新型口蹄疫病毒空衣壳样颗粒的免疫原性和保护效力
Vaccine. 2019 Mar 28;37(14):2016-2025. doi: 10.1016/j.vaccine.2019.02.032. Epub 2019 Feb 23.
8
Yeast Expression Systems: Overview and Recent Advances.酵母表达系统：概述与最新进展
Mol Biotechnol. 2019 May;61(5):365-384. doi: 10.1007/s12033-019-00164-8.
9
Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids.口蹄疫新型疫苗的研究进展：以重组空衣壳疫苗为重点。
Crit Rev Biotechnol. 2019 May;39(3):306-320. doi: 10.1080/07388551.2018.1554619. Epub 2019 Jan 17.
10
Foot and mouth disease vaccine strain selection: current approaches and future perspectives.口蹄疫疫苗株的选择：当前方法和未来展望。
Expert Rev Vaccines. 2018 Jul;17(7):577-591. doi: 10.1080/14760584.2018.1492378. Epub 2018 Jul 26.